Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

70.00EUR
19 Jan 2018
Change (% chg)

€-0.50 (-0.71%)
Prev Close
€70.50
Open
€69.50
Day's High
€70.50
Day's Low
€69.50
Volume
832
Avg. Vol
1,187
52-wk High
€81.75
52-wk Low
€65.00

Latest Key Developments (Source: Significant Developments)

NSAV Subsidiary Signs Agreement With Eli Lilly
Thursday, 14 Dec 2017 10:04am EST 

Dec 14 (Reuters) - Net Savings Link NSAV.PK::NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY.NET SAVINGS LINK SAYS VSRI WILL PROVIDE ELI LILLY WITH ASSESSMENT OF CVD AMONG NEWLY DIAGNOSED DIABETES PATIENTS AT INCREASED RISK OF CVD IN CHINA.  Full Article

Lilly Announces 2018 Financial Guidance, Enhances Outlook Through 2020
Wednesday, 13 Dec 2017 06:45am EST 

Dec 13 (Reuters) - Eli Lilly And Co ::LILLY ANNOUNCES 2018 FINANCIAL GUIDANCE AND ENHANCES OUTLOOK THROUGH 2020.SEES FY 2018 REVENUE $23 BILLION TO $23.5 BILLION.SEES FY 2017 EARNINGS PER SHARE $1.56 TO $1.66.SEES FY 2018 EARNINGS PER SHARE $4.24 TO $4.34.- REAFFIRMED ITS EXPECTATION OF AT LEAST 5 PERCENT AVERAGE ANNUAL REVENUE GROWTH FROM 2015 TO 2020, ON A CONSTANT CURRENCY BASIS.FY2017 EARNINGS PER SHARE VIEW $4.21 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.64, REVENUE VIEW $23.07 BILLION -- THOMSON REUTERS I/B/E/S.ELI LILLY - EXPECT OPERATING MARGIN AS PERCENT OF REVENUE TO BE AT LEAST 30 PERCENT IN 2020, EXCLUDING EFFECT OF FOREX ON INTERNATIONAL INVENTORIES SOLD.- ON A NON-GAAP BASIS, REAFFIRMED 2017 EPS TO BE IN RANGE OF $4.15 TO $4.25.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.60 TO $4.70.- SEES 2018 CAPITAL EXPENDITURES ABOUT $1.2 BILLION.ELI LILLY SEES 2018 REVENUE GROWTH DRIVEN BY NEW PRODUCTS INCLUDING TRULICITY, BASAGLAR, JARDIANCE, VERZENIO, OLUMIANT.ELI LILLY - REVISION TO 2017 EARNINGS PER SHARE OUTLOOK IS DUE TO CHANGES IN ESTIMATES RELATED TO ASSET IMPAIRMENT, RESTRUCTURING, OTHER SPECIAL CHARGES.  Full Article

Lilly Announces 8 Percent Dividend Increase
Monday, 11 Dec 2017 03:30pm EST 

Eli Lilly And Co ::LILLY ANNOUNCES 8 PERCENT DIVIDEND INCREASE.ELI LILLY AND CO - DIVIDEND FOR Q1 WILL BE $0.5625 PER SHARE ON OUTSTANDING COMMON STOCK.  Full Article

FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults
Monday, 11 Dec 2017 06:45am EST 

Dec 11 (Reuters) - Eli Lilly And Co ::FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS.ELI LILLY AND CO - ‍FDA ACCEPTED BLA TO REVIEW GALCANEZUMAB FOR PREVENTION OF MIGRAINE IN ADULTS​.  Full Article

Lilly's Cyramza meets Primary Endpoint in gastric cancer study
Friday, 8 Dec 2017 05:00pm EST 

Dec 8 (Reuters) - Eli Lilly And Co ::LILLY REPORTS TOP-LINE RESULTS FROM CYRAMZA® (RAMUCIRUMAB) PHASE 3 STUDY IN FIRST-LINE ADVANCED GASTRIC CANCER.ELI LILLY AND CO - TRIAL MET ITS PRIMARY ENDPOINT.ELI LILLY AND CO - PHASE 3 RAINFALL STUDY DID NOT IMPROVE OVERALL SURVIVAL (OS), A SECONDARY ENDPOINT.ELI LILLY - SAFETY PROFILE OBSERVED IN RAINFALL STUDY WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED FOR RAMUCIRUMAB.ELI LILLY AND CO - DOES NOT INTEND TO SEEK REGULATORY APPROVAL BASED ON RESULTS OF RAINFALL STUDY.ELI LILLY AND CO - OUTCOME OF RAINFALL DOES NOT HAVE ANY IMPACT ON CURRENT RAMUCIRUMAB APPROVALS.ELI LILLY AND CO - TWO OTHER ONGOING PHASE 3 STUDIES OF RAMUCIRUMAB ARE ONGOING, WITH EXPECTED DATA READOUTS IN 2018.  Full Article

Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
Wednesday, 6 Dec 2017 09:00am EST 

Dec 6 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION.JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS.JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478.JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED.  Full Article

Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018
Wednesday, 6 Dec 2017 06:25am EST 

Dec 6 (Reuters) - NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC::STILL EXPECTS TO LAUNCH OZEMPIC DIABETES DRUG IN JAPAN DURING THE FIRST HALF OF NEXT YEAR."WHEN IT COMES TO THE JAPANESE SITUATION WE ARE STILL EXPECTING TO MEET UP WITH THE COMMITTEE DURING THE COURSE OF JANUARY AND THEN BE ABLE TO WRAP UP THE LABEL, SO WE ARE EXPECTING ... TO LAUNCH DURING THE COURSE OF THE FIRST OF HALF OF NEXT YEAR ALSO IN JAPAN"."IN EUROPE WE SHOULD HOPE THAT THE ENDORSEMENT IS GIVEN BY THE CHMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE) DURING THE MONTH OF DECEMBER".THE U.S. FOOD AND DRUG ADMINISTRATION ON TUESDAY APPROVED NOVO'S DIABETES DRUG OZEMPIC, SETTING THE STAGE FOR A HEATED BATTLE WITH ELI LILLY & CO'S <<>> TRULICITY nL1N1O51MY.  Full Article

Eli Lilly initiates clinical trial to evaluate its automated insulin delivery system
Tuesday, 5 Dec 2017 09:00am EST 

Dec 5 (Reuters) - Eli Lilly And Co ::LILLY INITIATES CLINICAL TRIAL TO EVALUATE THE FUNCTIONALITY AND SAFETY OF ITS AUTOMATED INSULIN DELIVERY SYSTEM.  Full Article

Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Active Psoriatic Arthritis
Friday, 1 Dec 2017 05:01pm EST 

Dec 1 (Reuters) - Eli Lilly And Co ::LILLY'S TALTZ® (IXEKIZUMAB) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS.  Full Article

Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14
Wednesday, 22 Nov 2017 04:29pm EST 

Nov 22 (Reuters) - Eli Lilly And Co :Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing.  Full Article

Photo

U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing class of treatments.